Table 2

Secondary efficacy measures: point prevalence in percentages (intention to treat population eligible for response at baseline)

Outcome measure Time (week) Lam/interferon (n=68) Interferon (n=64) Lamivudine (n=80)
HBeAg loss2419 (62)11 (57)14 (70)
5235 (55)23 (56)23 (60)
6433 (55)29 (48)21 (62)
HBV DNA loss2484 (62)30 (57)64 (70)
5236 (55)29 (55)60 (60)
6431 (55)29 (49)32 (63)
ALT normalisation2434 (62)21 (58)51 (72)
5238 (55)29 (55)57 (58)
6436 (50)32 (50)21 (63)
  • HBeAg loss is defined as undetectable (AS×YM, Abbott); HBV DNA loss is defined as HBV DNA values below the cut off (3 pg/ml, Abbott HBV DNA test); ALT normalisation is defined as ⩽1.0×ULN. Number of patients is indicated in parentheses.